



ASX ANNOUNCEMENT

8 May 2019

HeraMED Expands European Distribution Network - Clarification

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) refers to the announcement lodged on 8 May referencing a binding Memorandum of Understanding (“MOU”) entered into with leading Turkish baby and toddler product distributor, Medizane Inc. (“Medizane”). The following clarifications to that announcement are:

- The initial purchase order of 1,000 units (**Initial Order**) has an estimated value of approximately US\$138,000 and must be made in the first 12 months and in any event on or before April 2020. Medizane thereafter purchase minimum quantities of 1,500 units before April 2021 and 1,950 units before April 2022. If Medizane fails to purchase those minimum quantities of product by the above stated dates, it will lose its exclusive right to distribute the products in the agreed territory of Turkey. All orders other than the Initial Order may, if of sufficient size, entitle Medizane to receive a price discount. The Company has the right to terminate the MOU with 90 days written notice, should Medizane fail to meet at least 85% of the minimum quantities set for each year.
- The MOU shall remain effective until 1 May, 2022 or until terminated by either Party’s written notice of six months to the other Party.

-ENDS-

HeraMED Limited

CEO and Co-Founder

David Groberman

M:+972-52-6991188

E: David@hera-med.com

Company Secretary

Stephen Buckley

T: +61 (0)8 6189 1155

E: stephen@companysecsol.com.au

Released through: Henry Jordan, Six Degrees Investor Relations, +61 431 271 538

About HeraMED Limited (ASX:HMD):

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving problems associated with the reliability of pre-natal analysis, as well as the cost and shortage in fundamental services through end-to-end medical grade solutions utilising monitoring devices, cloud based platforms and AI capabilities.

HeraMED is commercialising the worlds most advanced, smart medical grade ultrasound monitoring device HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.

HeraMED Limited ACN 626 295 314

T: +61 8 6189 1155 | A: Level 2, 46-50 Kings Park Road, West Perth WA 6005

For personal use only